Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients: Optical coherence tomography analysis

Soon Jun Hong, Seung Cheol Choi, Jae Young Cho, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do-Sun Lim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Aberrant expression of microRNAs is associated with neointimal hyperplasia (NIH) in type 2 diabetes. We prospectively compared the effects of pioglitazone on coronary NIH and changes in microRNAs according to NIH status in type 2 diabetic patients during 9-month follow-up. Methods and Results: Type 2 diabetic patients were randomly assigned to the pioglitazone (n=36) or control groups (n=36) after coronary stenting. Primary endpoint was the comparison of changes in neointimal volume on OCT and in the level of circulating microRNA-17,-24,-92a,-126 and -145 during 9-month follow-up. Secondary endpoint was the comparison of changes in brachial artery flow-mediated dilation and inflammatory markers such as IL-6, TNF-α, hsCRP, adiponectin, sICAM-1, and sVCAM-1 between the 2 groups. Neointimal volume was significantly lower in the pioglitazone group (25.02±17.78 mm3 vs. 55.10±30.01 mm3, P<0.001) with significant increases in circulating microRNA-24 (0.264±0.084 vs. 0.006±0.030, P<0.001) during follow-up. FMD was significantly greater in the pioglitazone than control group at 9 months (0.47±0.14 mm vs. 0.28±0.18 mm, P<0.05, respectively). Decreases in inflammatory markers such as IL-6, TNF-α, and sVCAM-1 were significantly greater in the pioglitazone than the control group during the follow-up. Conclusions: Pioglitazone significantly decreased NIH with increases in circulating microRNA-24 at 9-month followup. The decrease in microRNA-24 could be used as a potential predictor of increases in NIH in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)880-888
Number of pages9
JournalCirculation Journal
Volume79
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

pioglitazone
Optical Coherence Tomography
MicroRNAs
Hyperplasia
Control Groups
Interleukin-6
Brachial Artery
Adiponectin
Type 2 Diabetes Mellitus
Dilatation

Keywords

  • Diabetes
  • Endothelial function
  • MicroRNA
  • Pioglitazone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{28332d7be9bf4c2aa743b8e6fe6b1bd2,
title = "Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients: Optical coherence tomography analysis",
abstract = "Background: Aberrant expression of microRNAs is associated with neointimal hyperplasia (NIH) in type 2 diabetes. We prospectively compared the effects of pioglitazone on coronary NIH and changes in microRNAs according to NIH status in type 2 diabetic patients during 9-month follow-up. Methods and Results: Type 2 diabetic patients were randomly assigned to the pioglitazone (n=36) or control groups (n=36) after coronary stenting. Primary endpoint was the comparison of changes in neointimal volume on OCT and in the level of circulating microRNA-17,-24,-92a,-126 and -145 during 9-month follow-up. Secondary endpoint was the comparison of changes in brachial artery flow-mediated dilation and inflammatory markers such as IL-6, TNF-α, hsCRP, adiponectin, sICAM-1, and sVCAM-1 between the 2 groups. Neointimal volume was significantly lower in the pioglitazone group (25.02±17.78 mm3 vs. 55.10±30.01 mm3, P<0.001) with significant increases in circulating microRNA-24 (0.264±0.084 vs. 0.006±0.030, P<0.001) during follow-up. FMD was significantly greater in the pioglitazone than control group at 9 months (0.47±0.14 mm vs. 0.28±0.18 mm, P<0.05, respectively). Decreases in inflammatory markers such as IL-6, TNF-α, and sVCAM-1 were significantly greater in the pioglitazone than the control group during the follow-up. Conclusions: Pioglitazone significantly decreased NIH with increases in circulating microRNA-24 at 9-month followup. The decrease in microRNA-24 could be used as a potential predictor of increases in NIH in type 2 diabetic patients.",
keywords = "Diabetes, Endothelial function, MicroRNA, Pioglitazone",
author = "Hong, {Soon Jun} and Choi, {Seung Cheol} and Cho, {Jae Young} and Joo, {Hyung Joon} and Park, {Jae Hyoung} and Yu, {Cheol Woong} and Do-Sun Lim",
year = "2015",
doi = "10.1253/circj.CJ-14-0964",
language = "English",
volume = "79",
pages = "880--888",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "4",

}

TY - JOUR

T1 - Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients

T2 - Optical coherence tomography analysis

AU - Hong, Soon Jun

AU - Choi, Seung Cheol

AU - Cho, Jae Young

AU - Joo, Hyung Joon

AU - Park, Jae Hyoung

AU - Yu, Cheol Woong

AU - Lim, Do-Sun

PY - 2015

Y1 - 2015

N2 - Background: Aberrant expression of microRNAs is associated with neointimal hyperplasia (NIH) in type 2 diabetes. We prospectively compared the effects of pioglitazone on coronary NIH and changes in microRNAs according to NIH status in type 2 diabetic patients during 9-month follow-up. Methods and Results: Type 2 diabetic patients were randomly assigned to the pioglitazone (n=36) or control groups (n=36) after coronary stenting. Primary endpoint was the comparison of changes in neointimal volume on OCT and in the level of circulating microRNA-17,-24,-92a,-126 and -145 during 9-month follow-up. Secondary endpoint was the comparison of changes in brachial artery flow-mediated dilation and inflammatory markers such as IL-6, TNF-α, hsCRP, adiponectin, sICAM-1, and sVCAM-1 between the 2 groups. Neointimal volume was significantly lower in the pioglitazone group (25.02±17.78 mm3 vs. 55.10±30.01 mm3, P<0.001) with significant increases in circulating microRNA-24 (0.264±0.084 vs. 0.006±0.030, P<0.001) during follow-up. FMD was significantly greater in the pioglitazone than control group at 9 months (0.47±0.14 mm vs. 0.28±0.18 mm, P<0.05, respectively). Decreases in inflammatory markers such as IL-6, TNF-α, and sVCAM-1 were significantly greater in the pioglitazone than the control group during the follow-up. Conclusions: Pioglitazone significantly decreased NIH with increases in circulating microRNA-24 at 9-month followup. The decrease in microRNA-24 could be used as a potential predictor of increases in NIH in type 2 diabetic patients.

AB - Background: Aberrant expression of microRNAs is associated with neointimal hyperplasia (NIH) in type 2 diabetes. We prospectively compared the effects of pioglitazone on coronary NIH and changes in microRNAs according to NIH status in type 2 diabetic patients during 9-month follow-up. Methods and Results: Type 2 diabetic patients were randomly assigned to the pioglitazone (n=36) or control groups (n=36) after coronary stenting. Primary endpoint was the comparison of changes in neointimal volume on OCT and in the level of circulating microRNA-17,-24,-92a,-126 and -145 during 9-month follow-up. Secondary endpoint was the comparison of changes in brachial artery flow-mediated dilation and inflammatory markers such as IL-6, TNF-α, hsCRP, adiponectin, sICAM-1, and sVCAM-1 between the 2 groups. Neointimal volume was significantly lower in the pioglitazone group (25.02±17.78 mm3 vs. 55.10±30.01 mm3, P<0.001) with significant increases in circulating microRNA-24 (0.264±0.084 vs. 0.006±0.030, P<0.001) during follow-up. FMD was significantly greater in the pioglitazone than control group at 9 months (0.47±0.14 mm vs. 0.28±0.18 mm, P<0.05, respectively). Decreases in inflammatory markers such as IL-6, TNF-α, and sVCAM-1 were significantly greater in the pioglitazone than the control group during the follow-up. Conclusions: Pioglitazone significantly decreased NIH with increases in circulating microRNA-24 at 9-month followup. The decrease in microRNA-24 could be used as a potential predictor of increases in NIH in type 2 diabetic patients.

KW - Diabetes

KW - Endothelial function

KW - MicroRNA

KW - Pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=84925660941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925660941&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-14-0964

DO - 10.1253/circj.CJ-14-0964

M3 - Article

C2 - 25737017

AN - SCOPUS:84925660941

VL - 79

SP - 880

EP - 888

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 4

ER -